BPC-157 improved several measures of healing in animal experiments, but published human studies have not shown that it heals injuries or treats bowel disease. BPC-157 is a peptide, a short chain of 15 amino acids (the building blocks of proteins). The animal results have drawn interest in tendon repair, gut health, and recovery from injuries. Human trials still need to test those uses directly.
BPC-157 is also called a body protection compound in the literature. The name is a research label. Published patient reports, meeting abstracts, and animal experiments provide different levels of evidence, and each needs to be judged by what it measured.
The evidence map: many animal studies, very few human studies
Researchers have tested BPC-157 in several kinds of animal injury and in cells grown in laboratory dishes. The human record is much shorter. There are three small published reports: a retrospective knee-pain study, an uncontrolled bladder-pain study, and a two-person intravenous safety pilot. An older ulcerative colitis trial was described in a meeting abstract rather than a full peer-reviewed report. Another meeting abstract described a short safety and drug-handling study in healthy volunteers. These categories should not be counted as though they have equal weight.
The difference comes down to design. In a well-run randomized trial, chance assigns people to a treatment or comparison group, and ideally neither patients nor researchers know who received which treatment until the data are locked. That helps separate a drug effect from natural recovery, expectations, and differences between groups. A chart review or an uncontrolled series can identify an interesting signal, but it cannot isolate what caused improvement. An animal study is even farther from that answer because animals differ from people in anatomy, metabolism, injury patterns, and care.
Human knee pain: encouraging phone reports, weak causal evidence
The 2021 report by Lee and Padgett (https://pubmed.ncbi.nlm.nih.gov/34324435/) reviewed people who had received a BPC-157 injection into a painful knee. Seventeen patients were identified, and the researchers reached 16 by phone. Twelve had received BPC-157 alone; four had received BPC-157 together with another peptide, thymosin beta-4. Eleven of the 12 people in the BPC-only group reported some improvement, as did three of the four in the combined group.
Those figures sound impressive until the study design is considered. There was no untreated or placebo-injection comparison group. People with knee pain can improve because of rest, physical therapy, other treatments, natural fluctuation, or the simple passage of time. A phone call asking whether pain improved is valuable as a report of experience, but it is not the same as a preplanned, validated pain scale taken at fixed times. The study also did not demonstrate that damaged knee tissue had regrown. The four people who received two peptides cannot tell us which, if either, was responsible. The sample was too small to reveal uncommon side effects.
The proper conclusion is narrow: some patients said they felt better after an injection. That is a reason to run a controlled trial, not proof that BPC-157 heals knees. It does not establish how an oral capsule, nasal spray, or injection under the skin would compare with an injection directly into a joint.
Human bladder pain: twelve women, no control group
In a 2024 pilot study by Lee and colleagues (https://pubmed.ncbi.nlm.nih.gov/39325560/), 12 women with interstitial cystitis, a chronic condition that can cause bladder pain and frequent or urgent urination, received BPC-157 injections into the bladder wall during a cystoscopy procedure. A cystoscopy uses a small camera to look inside the bladder. The authors reported improvement in symptoms and no adverse events during the study.
This is worth investigating, especially because chronic bladder pain is difficult to live with. But all 12 participants received the intervention. Without a comparison group undergoing the same clinical attention and procedure without active BPC-157, the study cannot tell how much of the improvement came from the peptide. The setting, procedure, and route are also very specific: injecting medicine into the bladder wall is not equivalent to swallowing a pill or injecting a tendon. The report offers no basis for claims about sports recovery or whole-body healing.
The report of no adverse events in 12 people is reassuring only within that very small setting. If a side effect occurs once in a few hundred users, this study was unlikely to find it. Longer-term effects and risks in men or in people with other illnesses remain uncertain.
Human intravenous safety: two previously exposed adults
The 2025 pilot by Lee and Burgess (https://pubmed.ncbi.nlm.nih.gov/40131143/) involved two adults, one man and one woman, both of whom had previously received intravenous BPC-157. Each received 10 milligrams by infusion on one day and 20 milligrams the following day. Researchers checked vital signs, blood tests, and reported symptoms over three days. They observed no measured changes in their selected heart, kidney, liver, thyroid, or blood-sugar markers and no reported side effects.
This paper answers a very limited question: in these two previously exposed people, no acute problem was detected during the brief observation. It cannot establish that intravenous BPC-157 is generally safe, much less that long-term use is safe or effective. People who had already received the substance without an obvious problem may be less informative about first-time reactions. The study did not test injured patients or compare recovery with placebo. The absence of an event in two people should never be presented as a population-wide safety guarantee.
The older ulcerative colitis trial: why the abstract matters
Ulcerative colitis is a chronic inflammatory disease of the large intestine that can cause bleeding, diarrhea, pain, and serious complications. A 2005 meeting abstract described a randomized, double-blind, placebo-controlled study of BPC-157, also called PL 14736, given as an enema. An enema places liquid into the lower bowel. This is a more rigorous basic design than an uncontrolled patient series, so it deserves attention even though the report is incomplete.
The FDA's 2026 review of the original meeting abstract (https://www.fda.gov/media/193343/download) reports that 53 people with mild to moderate ulcerative colitis were randomly assigned to 80 milligrams of BPC-157 or placebo once a day for two weeks; 46 finished. The study used a disease activity index, a combined score intended to reflect symptoms, tests, and examination findings. The average score fell by 3.2 points in the BPC-157 group and 1.6 points in the placebo group. A falling score suggests improvement. However, the estimated difference between groups had a confidence interval that included no difference. A confidence interval is a range of effect sizes reasonably compatible with the data; when it crosses zero, this result does not clearly rule out the possibility that the apparent gap was due to chance.
The meeting abstract does not adequately explain who qualified for the trial, exactly how the score was calculated, the statistical methods, or what happened after the two treatment weeks. Five participants were withdrawn because of adverse events, three in the BPC-157 group and two in the placebo group; the authors described these withdrawals mainly as worsening colitis. One person in each group was lost to follow-up. The FDA concluded that the information was insufficient to establish efficacy or safety for treating ulcerative colitis. The trial happened, but the available report cannot show that the treatment works.
The same FDA document describes an earlier placebo-controlled safety and drug-handling study reported only in 2002 and 2003 meeting abstracts. Thirty-two healthy volunteers were randomized, 24 of whom received BPC-157 by enema at different doses. The abstract reported no significant short-term adverse events attributable to treatment, with headache and gas among the commonly reported events. Because a full report is unavailable and the groups were small, it cannot settle wider safety questions. These older enema studies also cannot support claims about capsules, skin injections, or nasal sprays.
Rat tendon studies: what the researchers measured
One frequently cited 2003 Achilles-tendon study by Staresinic and colleagues (https://pubmed.ncbi.nlm.nih.gov/14554208/) deliberately cut rats' Achilles tendons and then examined repair after BPC-157 treatment. The investigators also studied tendon cells grown in a dish. They reported improved healing-related measures in the treated animals and changes in tendon-cell growth. The researchers created a defined injury, treated it, and compared tissue responses.
But a clean surgical cut in a rat is not a chronic human tendon problem. Many painful tendons are overloaded or degenerative rather than fully severed. People also vary in age, activity, underlying disease, and rehabilitation. Laboratory tendon-cell growth is not proof that a human tendon will regain strength, function, and low pain. The animal result is a strong reason to ask the human question; it is not the answer to it.
A 2010 rat study of the medial collateral ligament (https://pubmed.ncbi.nlm.nih.gov/20225319/) examined a different knee structure. A ligament connects bones to each other. Researchers surgically transected the ligament and looked at tissue, functional, and mechanical outcomes with BPC-157 given by different routes. They reported better healing measures in treated animals. Mechanical testing matters because a ligament that merely looks repaired under a microscope may still fail under load. Even so, an animal ligament's measured strength does not establish that a human can safely return to sport earlier after using BPC-157.
In a 2008 rat muscle-crush experiment (https://pubmed.ncbi.nlm.nih.gov/18668315/), investigators injured muscle and assessed recovery over about two weeks. They reported improvements with BPC-157 on healing measures. Again, the injury was standardized and the observation period short. The result does not tell us whether the peptide helps a human muscle strain, at what dose, or whether repeated use has delayed harms. A 2025 rat quadriceps-repair study (https://pubmed.ncbi.nlm.nih.gov/39861766/) adds another surgical muscle-injury model, but it does not turn the human evidence gap into a solved problem.
Several papers in this area come from overlapping research teams and closely related models. Repeating a technique in animals can strengthen a biological hypothesis. Independent human replication is still necessary before anyone can claim that BPC-157 reliably heals human injuries.
Gut, nerve, and blood-vessel claims
BPC-157's history includes digestive-tract research. A 2008 rat fistula study (https://pubmed.ncbi.nlm.nih.gov/18649140/) examined abnormal connections involving the stomach and reported repair-related effects. A fistula is an unwanted passage between tissues. That is a specific experimental condition, not the same as ordinary indigestion, irritable bowel syndrome, or ulcerative colitis in a person. The human colitis abstract discussed above is the clinically relevant test and remains inconclusive.
A 2010 rat nerve-injury experiment (https://pubmed.ncbi.nlm.nih.gov/19903499/) reported effects after peripheral nerve damage. Peripheral nerves carry signals between the brain and body. Nerve recovery can be assessed in many ways, from tissue appearance to movement and sensation. This model supports a research question about nerve repair. It does not demonstrate that BPC-157 reverses human neuropathy or spinal-cord injury. Claims about entirely different neurological diseases require their own human trials.
Some researchers have proposed that BPC-157 affects the formation of blood vessels and chemical signals involved in repair. Such mechanisms could help explain animal observations, but there are reasons to be careful with broad claims. New blood vessels can be useful in wound healing, while abnormal vessel growth may be undesirable in other contexts. A signal that looks helpful after a controlled injury is not automatically beneficial for every disease or every patient. Mechanism should guide testing, not stand in for outcome data.
Route, dose, and product quality are part of the question
Any claim about BPC-157 needs to specify the preparation, how it was given, and what outcome changed. The 2022 pharmacokinetic study in rats and beagles (https://pubmed.ncbi.nlm.nih.gov/36588717/) examined how quickly BPC-157 moved through those animals' bodies and compared delivery routes. Pharmacokinetics means the body's handling of a substance: how it enters the bloodstream, spreads, and disappears. The study reported rapid loss from blood and route-dependent exposure. Animal blood levels cannot be used to calculate a safe or effective human dose, and they do not prove that oral and injectable products are interchangeable.
This matters because the human knee study used joint injections, the bladder study used bladder-wall injections, the tiny safety pilot used infusions, and the older colitis study used enemas. None of them establishes that a consumer capsule, nasal spray, or home injection has the same effect. Laboratory preparation quality also differs from what may be sold online. If a product's identity, purity, and concentration are uncertain, even a sound study of a known preparation cannot predict that product's risks or benefits.
The FDA's assessment of certain compounded peptides (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) has raised concerns about limited human safety information and possible problems such as peptide impurities or immune reactions. An immune reaction is an unwanted response from the body's defense system. This does not mean every exposure is dangerous; it means the evidence is insufficient to assume safety from the small reports available. BPC-157 is investigational, not an FDA-approved treatment for tendon injury, bowel disease, or bladder pain.
What would change the picture?
For an injury claim, the useful study would enroll enough people with a clearly defined injury, randomly assign them to BPC-157 or an appropriate comparison, keep both groups on the same rehabilitation plan, and measure pain, physical function, return to activity, and adverse effects at planned times. Imaging alone would not suffice if people did not feel or function better. For gut disease, a trial would need accepted measures of remission, bleeding, bowel frequency, and endoscopic findings, with enough follow-up to see whether improvement lasts.
Researchers would also need to report the exact product, dose, route, and quality checks, then repeat positive findings independently. Safety cannot be established by saying no one in a group of two or twelve reported a problem. A more substantial safety database, including follow-up for uncommon and delayed events, would be needed.
The fair conclusion is that BPC-157 has a substantial collection of preclinical findings worth investigating and only fragmentary human evidence. The human studies do not yet show that it heals tendons, repairs the gut, or reliably relieves pain. They also do not define a proven safe way to use it. Anyone dealing with a persistent injury or bowel condition deserves a proper diagnosis and treatments whose benefits and risks are better established while this research continues.
